Chinese biotech dominance in R&D is on the rise
Against a backdrop of rising U.S.-China geopolitical tensions, there are signs of growing dealmaking activity between Western ...
pharmaphorum3h
AZ, Daiichi get FDA nod for Dato-DXd in breast cancer
The US regulator has cleared TROP2-directed ADC datopotamab deruxtecan (Dato-DXd) under the Datroway trade name as a ...
ジャパンタイムズ11h
AstraZeneca and Daiichi Sankyo win U.S. approval for breast cancer drug
The Food and Drug Administration approved the drug for patients with advanced breast tumors whose cells bear a certain ...
Tuoi Tre news16h
US FDA approves AstraZeneca's drug for breast cancer
The U.S. Food and Drug Administration has approved AstraZeneca and partner Daiichi Sankyo's precision drug to treat a type of breast cancer, the health regulator said on Friday.
FDA Okays AstraZeneca And Daiichi's Datroway For Metastatic HR-Positive, HER2-Negative Breast Cancer
The U.S. Food and Drug Administration approved AstraZeneca (AZN, AZN.L) and Daiichi Sankyo's (DSKYF.PK) Datroway (datopotamab ...
The Financial Express18h
Africa reports over 200 disease outbreaks in 2024; Cholera tops list
Health emergencies are on the rise in Africa. Last year, there were 213 public health outbreaks that the pan-African public ...
Hosted on MSN19h
AstraZeneca’s Datroway approved in U.S. for HER2-negative breast cancer patients
DXd, has been approved in the US for the treatment of adult patients with unresectable or metastatic hormone receptor HR-positive, HER2-negative breast cancer who have received prior endocrine-based ...
AZN INVESTOR ALERT: AstraZeneca PLC Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit
If you suffered substantial losses and wish to serve as lead plaintiff of the AstraZeneca class action lawsuit, please provide your information here: You can also contact attorneys J.C. Sanchez or ...